ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2023-5.384 ResearchBib IF: 8.848 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-4, ISSUE-4

UDC: 616.71-003.84:616.43

DIABETES MELLITUS AND OSTEOPOROSIS: A MODERN VIEW OF THE PROBLEM AND TREATMENT OPTIONS

Saidjonova Feruza Latifjonovna
Assistant
Department of Pathological Anatomy
Andijan State Medical Institute
dilbarabdurazzakova7@gmail.com
+998902017510

Abstract:

Diabetes mellitus (DM) and osteoporosis are two prevalent metabolic disorders that often coexist, presenting a complex interplay with significant clinical implications. This paper aims to provide a comprehensive overview of the relationship between DM and osteoporosis, exploring underlying mechanisms, shared risk factors, and potential treatment strategies. A thorough literature review was conducted, examining recent research findings and clinical studies on this topic. The paper discusses the impact of DM on bone metabolism, the role of insulin signaling pathways, and the influence of chronic hyperglycemia on bone tissue. Furthermore, it explores the bidirectional relationship between DM and osteoporosis, highlighting how osteoporosis may exacerbate diabetic complications and vice versa. Various treatment options, including lifestyle modifications, pharmacotherapy, and emerging therapies targeting both DM and osteoporosis, are also discussed. Overall, a multidisciplinary approach integrating diabetes management and osteoporosis prevention is crucial for optimizing patient outcomes and reducing the burden of these interconnected conditions.

Keywords: Diabetes mellitus, osteoporosis, bone metabolism, insulin signaling, treatment options.

Introduction:

Diabetes mellitus (DM) and osteoporosis are prevalent chronic conditions that pose significant public health challenges worldwide. DM, characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both, affects approximately 463 million adults globally [1]. Osteoporosis, a skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, predisposes individuals to increased fracture risk and associated morbidity and mortality [2]. While traditionally viewed as distinct entities,

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2023-5.384 ResearchBib IF: 8.848 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-4, ISSUE-4

accumulating evidence suggests a complex interplay between DM and osteoporosis, with implications for disease pathogenesis, management, and outcomes.

Pathophysiology of Diabetes Mellitus and Osteoporosis:

The pathophysiology of DM involves multiple mechanisms, including insulin resistance, impaired insulin secretion, and chronic hyperglycemia, which contribute to systemic metabolic derangements and end-organ complications [3]. Notably, insulin exerts direct effects on bone metabolism, with insulin receptors present on osteoblasts and osteoclasts, suggesting a regulatory role in bone formation and resorption [4].

Chronic hyperglycemia in DM promotes oxidative stress, advanced glycation end-products (AGEs) formation, and inflammation, which adversely affect bone health by impairing osteoblast function, increasing osteoclast activity, and altering the composition of the extracellular matrix. Furthermore, dysregulation of the insulin signaling pathway in DM may disrupt bone homeostasis, leading to reduced bone formation and increased bone resorption [5, 6]. In addition to the direct effects of DM on bone, shared risk factors such as aging, sedentary lifestyle, and nutritional deficiencies contribute to the development of osteoporosis in individuals with DM [7]. Moreover, diabetic complications, including neuropathy and nephropathy, may exacerbate bone fragility and fracture risk. Conversely, osteoporosis-related fractures may compromise mobility and exacerbate glycemic control in individuals with DM, creating a vicious cycle of skeletal and metabolic dysfunction [8, 9].

Epidemiology and Clinical Implications:

The coexistence of DM and osteoporosis poses substantial clinical implications, including an increased risk of fragility fractures, functional impairment, and mortality [10]. Epidemiological studies have demonstrated a higher prevalence of osteoporosis and fractures in individuals with DM compared to non-diabetic counterparts, independent of traditional fracture risk factors. Moreover, fractures in individuals with DM are associated with poorer outcomes, including delayed healing, increased complications, and higher mortality rates [11, 12].

Treatment Strategies:

The management of individuals with both DM and osteoporosis requires a multifaceted approach addressing metabolic control, bone health, and fracture prevention. Lifestyle interventions, including weight-bearing exercise, adequate calcium and vitamin D intake, and smoking cessation, are fundamental components of osteoporosis prevention and management in individuals with DM [13].

Pharmacotherapy plays a crucial role in the management of osteoporosis and may have additional benefits in individuals with DM. Antiresorptive agents such as bisphosphonates, denosumab, and selective estrogen receptor modulators (SERMs)

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2023-5.384 ResearchBib IF: 8.848 / 2024

are commonly used to reduce fracture risk and preserve bone mass in osteoporotic individuals. However, caution is warranted when prescribing these agents in individuals with DM, as some medications may impact glucose metabolism or interact with antidiabetic medications [14, 15].

Emerging therapies targeting both DM and osteoporosis hold promise for improving outcomes in this population. For example, incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been shown to exert favorable effects on bone metabolism and may have potential implications for fracture prevention in individuals with DM [16]. Additionally, newer antidiabetic agents, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dual peroxisome proliferator-activated receptor (PPAR) agonists, are under investigation for their effects on bone health and fracture risk reduction [17].

Conclusion:

In conclusion, the relationship between DM and osteoporosis represents a complex interplay with significant clinical implications. Understanding the underlying mechanisms linking these conditions and implementing multidisciplinary management strategies are essential for optimizing patient outcomes and reducing the burden of these interconnected disorders. Further research is needed to elucidate the mechanistic pathways involved and identify novel therapeutic targets for the prevention and treatment of osteoporosis in individuals with DM.

References:

1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.

2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.

3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90.

4. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735-E745.

5. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21(2):195-214.

6. Starup-Linde J. Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol (Lausanne). 2013;4:21.

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2023-5.384 ResearchBib IF: 8.848 / 2024

7. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18(4):427-444.

8. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208-219.

9. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184-2192.

10. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505.

11. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404-3410.

12. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. 2009;84(1):45-55.

13. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16(12):1713-1720.

14. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone. 2011;48(4):720-725.

15. Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS Study. Diabetologia. 2014;57(10):2057-2065.

16. Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014;63(12):1480-1490.

17. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48(7):1292-1299.

18. Сахарный диабет: Клиника, диагностика, лечение" (Diabetes Mellitus: Clinical Presentation, Diagnosis, Treatment), В.И. Дедов, Э.В. Шестакова.

19. "Остеопороз: патогенез, диагностика, лечение" (Osteoporosis: Pathogenesis, Diagnosis, Treatment), М.А. Кобылянский and С.В. Лишенко.